Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Freeman-Keller, Morganna, Kim, Youngchul, Cronin, Heather, Richards, Allison, Gibney, Geoffrey, Weber, Jeffrey S.·2016·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-15-1136

Cited by (860)

Items 201–300 of 860

Emerging biomarkers for cancer immunotherapy in melanoma
Margaret L. Axelrod, Douglas Buckner Johnson, Justin Micah Balko · 2017 · Seminars in Cancer Biology
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
Mari Aso, Yukihiro Toi, Jun Sugisaka, Tomoiki Aiba, Sachiko Kawana, Ryohei Saito, Takahiro Ogasawara, Kyoji Tsurumi, Kana Ono, Hisashi Shimizu et al. · 2019 · The Oncologist
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Maria Kfoury, Marie Najean, Ariane Lappara, Anne-Laure Voisin, Stéphane Champiat, Jean‐Marie Michot, Salim Laghouati, Caroline Robert, Benjamin Besse, Jean‐Charles Soria et al. · 2022 · Cancer Treatment Reviews
Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers
Taku Fujimura, Setsuya Aiba · 2020 · Biomolecules
Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
Ling Zhan, Hong-Fang Feng, Hanqing Liu, Liantao Guo, Chuang Chen, Xiao-li Yao, Shengrong Sun · 2021 · Frontiers in Endocrinology
Overview of current and future systemic therapy for metastatic renal cell carcinoma
Takahiro Osawa, Ario Takeuchi, Takahiro Kojima, Nobuo Shinohara, Masatoshi Eto, Hiroyuki Nishiyama · 2019 · Japanese Journal of Clinical Oncology
Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study
Eiji Nakano, Akira Takahashi, Kenjiro Namikawa, Yusuke Muto, Shunichi Jinnai, Yuta Kage, Haruki Mizuta, Arata Tsutsumida, Naoya Yamazaki · 2020 · The Journal of Dermatology
Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
Shicong Zhu, Yang Fu, Bo Zhu, Bicheng Zhang, Jun Wang · 2020 · Frontiers in Oncology
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
Zoé Apalla, Chryssoula Papageorgiou, Aimilios Lallas, Florentina Silvia Delli, Christina Fotiadou, Christina Kemanetzi, Elizabeth Lazaridou · 2021 · Dermatology Practical & Conceptual
Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging
Nemi Gandy, Mubarik Arshad, Kathryn L. Wallitt, Suraiya Dubash, Sameer Khan, Tara D. Barwick · 2020 · British Journal of Radiology
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, Wonyoung, Won, Taejoon, Daoud, Abdel, Čiháková, Daniela · 2024 · Frontiers in Immunology
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
Hiroki Nagai, Manabu Muto · 2018 · International Journal of Clinical Oncology
A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
Yuanyuan Wang, Tingxuan Gu, Xueli Tian, Wenwen Li, Ran Zhao, Wenqian Yang, Quanli Gao, Tiepeng Li, Jung‐Hyun Shim, Chengjuan Zhang et al. · 2021 · Frontiers in Immunology
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study
Wenxian Wang, Xiaodong Gu, Liping Wang, Xingxiang Pu, Huijing Feng, C. Xu, Guangyuan Lou, Lan Shao, Yibing Xu, Qian Wang et al. · 2021 · Cancer Immunology Immunotherapy
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Yi-Shan Teng, Sebastian Yu · 2023 · Current Oncology
Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment
Yaxin Du, Wenjie Wu, Mei Chen, Zhengbang Dong, Fei Wang · 2023 · JAMA Dermatology
Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
Yael Eshet, Erez N. Baruch, Ronnie Shapira‐Frommer, Yael Steinberg‐Silman, Teodor Kuznetsov, Guy Ben‐Betzalel, Sameh Daher, Iris Gluck, Nethanel Asher, Sara Apter et al. · 2018 · Cancer Immunology Research
Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review
A Ram Hong, Jee Hee Yoon, Hee Kyung Kim, Ho‐Cheol Kang · 2020 · Frontiers in Endocrinology
The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes
Hamzah Abu‐Sbeih, Tenglong Tang, Faisal S. Ali, Daniel Hartman Johnson, Wei Qiao, Adi K. Diab, Yinghong Wang · 2018 · Journal of Immunotherapy and Precision Oncology
Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study
Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura et al. · 2021 · Journal of Cancer
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Boland, Patrick, Pavlick, Anna C, Weber, Jeffrey, Sandigursky, Sabina · 2020 · Journal for ImmunoTherapy of Cancer
Cutaneous adverse events: a predictor of tumour response under anti‐ PD ‐1 therapy for metastatic melanoma, a cohort analysis of 189 patients
L. Bottlaender, Mona Amini‐Adlé, Delphine Maucort‐Boulch, P. Robinson, Luc Thomas, Stéphane Dalle · 2020 · Journal of the European Academy of Dermatology and Venereology
Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
Hiroki L. Yamaguchi, Yuji Yamaguchi, Elena Peeva · 2024 · International Journal of Molecular Sciences
Clinical features of immune‑related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD‑1 blockade
Tomoki Sakakida, Takeshi Ishikawa, Junji Uchino, Yusuke Chihara, Satoshi Komori, Jun Asai, Tsukasa Narukawa, Akihito Arai, Tsutomu Kobayashi, Hiroaki Tsunezuka et al. · 2019 · Oncology Letters
Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study
Isaku Okamoto, Hiroki Sato, Takahito Kondo, Nobuyuki Koyama, Chihiro Fushimi, Takuro Okada, Kouki Miura, Takashi Matsuki, Taku Yamashita, Go Omura et al. · 2019 · Acta Oto-Laryngologica
Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors
Louis Gaucher, Leslie Adda, Alice Séjourné, Camille Joachim, GUILLAUME CHABY, Claire Poulet, Sophie Liabeuf, Valérie Gras‐Champel, Kamel Masmoudi, Aline Houessinon et al. · 2021 · Therapeutic Advances in Medical Oncology
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
Weiyu Ye, Anna Claire Olsson-Brown, Robert A. Watson, Vincent Cheung, Robert David Morgan, Isar Nassiri, Rosalin A. Cooper, Chelsea Alice Taylor, Umair Akbani, Oliver Brain et al. · 2021 · British Journal of Cancer
Safety and efficacy of nivolumab in the treatment of cancers: A meta‐analysis of 27 prospective clinical trials
Yan Tie, Xuelei Ma, Chenjing Zhu, Mao Ye, Kai Shen, Xiawei Wei, Yan Chen, Heng Zheng · 2016 · International Journal of Cancer
The Impact of Antibiotics on Prognosis of Metastatic Renal Cell Carcinoma in Japanese Patients Treated With Immune Checkpoint Inhibitors
Kosuke Ueda, Satoru Yonekura, Naoyuki Ogasawara, Yoshihiro Matsunaga, Ryuji Hoshino, Hirofumi Kurose, Katsuaki Chikui, Keiichiro Uemura, Makoto Nakiri, Kiyoaki Nishihara et al. · 2019 · Anticancer Research
Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
Maria Grigoriou, Aggelos Banos, Aikaterini Hatzioannou, Andreas Kloetgen, Panagiotis Kouzis, Despoina Aggouraki, Roubini Zakopoulou, Giorgos Bamias, Eva N. Kassi, Dimitriοs Mavroudis et al. · 2021 · Cancer Immunology Research
Radiologic Features of Pneumonitis Associated With Nivolumab in Non-Small-Cell Lung Cancer and Malignant Melanoma
Tomohisa Baba, Fumikazu Sakai, Terufumi Kato, Masahiko Kusumoto, Hirotsugu Kenmotsu, Hiroaki Sugiura, Junya Tominaga, Katsunori Oikado, Masafumi Sata, Masahiro Endo et al. · 2019 · Future Oncology
Triggers of inflammatory myopathy: insights into pathogenesis.
Brittany L. Adler, Lisa Christopher‐Stine · 2018 · PubMed
The dark side of immunotherapy
Nwanneka Okwundu, Douglas Grossman, Siwen Hu‐Lieskovan, Kenneth F. Grossmann, Umang Swami · 2021 · Annals of Translational Medicine
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
Melissa L. Bastacky, Hong Wang, Dylan D. Fortman, Zahra Rahman, Gerard P. Mascara, Timothy Brenner, Yana George Najjar, Jason J. Luke, John M. Kirkwood, Hassane M. Zarour et al. · 2021 · Frontiers in Oncology
Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient‐derived induced pluripotent stem cells for future research
Yoshiya Hosokawa, Toshiaki Hanafusa, Akihisa Imagawa · 2019 · Journal of Diabetes Investigation
The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study
R. Dupont, E. Bérard, Florent Puisset, Thibault Comont, Jean‐Pierre Delord, Rosine Guimbaud, Nicolás Meyer, Julien Mazières, Laurent Alric · 2019 · OncoImmunology
Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications
Julia‐Tatjana Maul, Carole Guillet, Anna Oschmann, Lara Valeska Maul, Barbara Meier-Schiesser, Pia‐Charlotte Stadler, Lars Einar French, Katrin Kerl · 2023 · Journal of the European Academy of Dermatology and Venereology
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Taito Fukushima, Manabu Morimoto, Satoshi Kobayashi, Makoto Ueno, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Makoto Chuma, Kazushi Numata, Kota Tsuruya et al. · 2023 · The Oncologist
Treatment of immune checkpoint inhibitor-induced inflammatory arthritis
Susanna Jeurling, Laura C. Cappelli · 2020 · Current Opinion in Rheumatology
Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
Michelle Coureau, Anne‐Pascale Meert, Thierry Berghmans, Bogdan Dragoş Grigoriu · 2020 · Frontiers in Medicine
Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
Moataz Ellithi, Radowan A. Elnair, Guy vin Chang, Mohamed A Abdallah · 2020 · Cureus
Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
Lin Li, Yu Liu, Chen Chen, Anhua Wei, Wěi Li · 2023 · Frontiers in Pharmacology
Immune-Related Adverse Events: A Case-Based Approach
Caoilfhionn Marie Connolly, Kalindi Bambhania, Jarushka Naidoo · 2019 · Frontiers in Oncology
Dermatologic conditions in women receiving systemic cancer therapy
Michelle Ferreira, Julie Y. Ramseier, Jonathan Scott Leventhal · 2019 · International Journal of Women’s Dermatology
The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno · 2024 · Japanese Journal of Clinical Oncology
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
David Wai-Meng Tai, Su Pin Choo, Valerie Chew · 2019 · Cancers
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Katsuya Hirano, Hirotaka Matsumoto et al. · 2020 · Clinical Lung Cancer
Expert opinion on thyroid complications in immunotherapy
F. Illouz, D. Drui, Philippe Jean Caron, Christine Do Cao · 2018 · Annales d Endocrinologie
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Samantha L. Bucktrout, Jeffrey A. Bluestone, Fred Ramsdell · 2018 · Genome Medicine
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A. Ascierto, John B.A.G. Haanen, Enrique Espinosa, Лев Вадимович Демидов, Claus Garbe, Michele Guida, Paul C. Lorigan, Vanna Chiarion‐Sileni, Helen J Gogas et al. · 2019 · European Journal of Cancer
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
Brian William Labadie, Ping Liu, Riyue Bao, Michael Crist, Ricardo Fernandes, Laura Ferreira, Scott Graupner, Andrew Stewart Poklepovic, Ignacio Durán, Saman Maleki Vareki et al. · 2019 · Journal of Translational Medicine
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
Editta Baldini, Alice Lunghi, Enrico Cortesi, Daniele Turci, Diego Signorelli, Valeria Stati, Barbara Melotti, Biagio Ricciuti, Antonio Frassoldati, Giampiero Romano et al. · 2019 · Lung Cancer
Immune Checkpoint Inhibitor-Induced Hypophysitis: Lessons Learnt from a Large Cancer Cohort
Anupam Kotwal, Samuel G Rouleau, Surendra Dasari, Lisa A. Kottschade, Mabel M. Ryder, Yogish C. Kudva, Svetomir N. Markovic, Dana Z. Erickson · 2021 · Journal of Investigative Medicine
Immune-related adverse events by immune checkpoint inhibitors
Takafumi Kadono · 2017 · Japanese Journal of Clinical Immunology
Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study
Kenjiro Namikawa, Akira Takahashi, Taisuke Mori, Arata Tsutsumida, Shigenobu Suzuki, Noriko Motoi, Shunichi Jinnai, Yuta Kage, Haruki Mizuta, Yusuke Muto et al. · 2019 · Melanoma Research
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
Andrew C. Johns, Lai Wei, Madison M. Grogan, Rebecca Hoyd, John F. P. Bridges, Sandipkumar H. Patel, Mingjia Li, Marium Husain, Kari Lynn Kendra, Gregory A. Otterson et al. · 2021 · Journal of Geriatric Oncology
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Megan Leila Baker, Yu Yamamoto, Mark Anthony Perazella, Nazlı Dizman, Anushree C. Shirali, Navid Hafez, Jason N. Weinstein, Michael Simonov, Jeffrey M. Testani, Harriet M. Kluger et al. · 2022 · Journal for ImmunoTherapy of Cancer
Immunothérapie des cancers : rationnel et avancées récentes
Clémence Granier, Soumaya Karaki, H. Roussel, Cécile Badoual, Thi Tran, Marie Anson, Elizabeth Fabre, Stéphane Marie. Oudard, Éric Tartour · 2016 · La Revue de Médecine Interne
Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Alexandra K. Rzepecki, Haiying Cheng, Beth N. McLellan · 2018 · Journal of the American Academy of Dermatology
Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients
Pauline Campredon, Céline Mouly, Amélie Lusque, Laurence Bigay-Game, Emilie Bousquet, Julien Mazières, Philippe Jean Caron · 2019 · La Presse Médicale
Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141)
Chia‐Jui Yen, Naomi Kiyota, Nobuhiro Hanai, Shunji Takahashi, Tomoya Yokota, Shigemichi Iwae, Yasushi Shimizu, Ruey‐Long Hong, Masahiro Goto, Jin‐Hyoung Kang et al. · 2020 · Head & Neck
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
Hazim S. Bukamur, Heather Katz, Mohamed Farouq Alsharedi, Akram Alkrekshi, Yousef Shweihat, Nancy J. Munn · 2020 · Southern Medical Journal
Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors
Nicole A. Romanski, Rikke Boedker Holmstroem, Eva Ellebæk, Inge Marie Svane · 2020 · European Journal of Cancer
Immune Checkpoint Inhibitors and Neurotoxicity
Zhiyi Zhao, Chunlin Zhang, Lian Zhou, Pan Dong, Lei Shi · 2020 · Current Neuropharmacology
Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors
Cho‐Han Chiang, Cho‐Hung Chiang, Chun-Yu Peng, Yuan Ping Hsia, Xin Ya See, Chuan‐Sheng Horng, Yu-Cheng Chang, Xuan-Er Shen, Shih‐Syuan Wang, Tien-Chi Tsai et al. · 2022 · European Journal of Cancer
Steroid hormones as modulators of anti-tumoural immunity
Paul Schwarzlmueller, Alexandra S. Triebig, Guillaume Assié, Anne Jouinot, Sebastian Theurich, Tanja Maier, Felix Beuschlein, Sebastian Kobold, Matthias Kroiß · 2025 · Nature Reviews Endocrinology
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
Brendan D. Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy C. Gregory et al. · 2017 · Journal for ImmunoTherapy of Cancer
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitor
Norikazu Matsuo, Koichi Azuma, Satoshi Hattori, Junya Ohtake, Akihiko Kawahara, Hidenobu Ishii, Takaaki Tokito, Kazuhiko Yamada, Yuji Shibata, Tadasuke Shimokawaji et al. · 2018 · International Journal of Cancer
PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer
Sandra Heskamp, Peter J. Wierstra, Janneke D.M. Molkenboer‐Kuenen, Gerwin W. Sandker, Soley Thordardottir, Jeannette Cany, Daniel Olive, Johan Bussink, Otto C. Boerman, Harry Dolstra et al. · 2018 · Cancer Immunology Research
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events
Diwakar Davar, John M. Kirkwood · 2019 · JAMA Oncology
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
Kenji Morimoto, Tadaaki Yamada, Chieko Takumi, Yuri Ogura, Takayuki Takeda, Keisuke Onoi, Yusuke Chihara, Ryusuke Taniguchi, Takahiro Yamada, Osamu Hiranuma et al. · 2021 · Frontiers in Oncology
Updates in SJS/TEN: collaboration, innovation, and community
Madeline E. Marks, Ramya Krishna Botta, Riichiro Abe, Thomas M. Beachkofsky, Isabelle Boothman, Bruce Carleton, Wen‐Hung Chung, Ricardo R. Cibotti, Roni P. Dodiuk‐Gad, Christian Grimstein et al. · 2023 · Frontiers in Medicine
Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management
Shelley Ji Eun Hwang, R. Anforth, G. Carlos, Pablo Fernández‐Peñas · 2016 · Actas Dermo-Sifiliográficas
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Wouter Ouwerkerk, Mirjam van den Berg, Sanne van der Niet, Jacqueline Limpens, Rosalie M. Luiten · 2019 · Melanoma Research
Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature
Cory Kosche, Molly J. Stout, Jeffrey Alan Sosman, Rimas Vincas Lukas, Jennifer Nam Choi · 2019 · Melanoma Research
Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Mike Sung, Alona Zer, Preet Walia, Leila Khoja, Manjula D. Maganti, Catherine Labbé, Frances A. Shepherd, Penelope A. Bradbury, Geoffrey Liu, Natasha B. Leighl · 2020 · Journal of Thoracic Disease
Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences
Brandon E. Cohen, Prashiela Manga, Krysta Lin, Nada Elbuluk · 2020 · American Journal of Clinical Dermatology
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls
Steve Y. Cho, Daniel T. Huff, R. Jeraj, M. Albertini · 2020 · Seminars in nuclear medicine
Cutaneous immune-related adverse events to checkpoint inhibitors
Neeta Malviya, Ian Tattersall, Jonathan Scott Leventhal, Allireza Alloo · 2020 · Clinics in Dermatology
Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
Lynn Massman Rose, Hannah A. DeBerg, Prakash Vishnu, Jason Frankel, Adarsh B. Manjunath, John Paul Flores, David Michael Aboulafia · 2021 · Frontiers in Oncology
Immune-related cutaneous adverse events due to checkpoint inhibitors
Evelyn Wang, Lukas Kraehenbuehl, Kwami F. Ketosugbo, Jeffrey A. Kern, Mario E. Lacouture, Donald Y.M. Leung · 2021 · Annals of Allergy Asthma & Immunology
Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation
Louis Gaucher, Leslie Adda, Alice Séjourné, Camille Joachim, G. Chaby, Claire Poulet, Sophie Liabeuf, Valérie Gras‐Champel, Kamel Masmoudi, Aurélie Moreira et al. · 2021 · Therapeutic Advances in Medical Oncology
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
Rossella Rubino, Andrea Marini, Giandomenico Roviello, Elena Margherita Presotto, Isacco Desideri, Isabella Ciardetti, Marco Brugia, Nicola Pimpinelli, Lorenzo Antonuzzo, Enrico Mini et al. · 2021 · Endocrine
Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study
Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura et al. · 2023 · Cancer Medicine
To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease
Morgan Alexandra Pantuck, David F. McDermott, Alexandra Drakaki · 2019 · Cancer
Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillance
Kenji Ishitsuka, Satoshi Yurimoto, Kouichi Kawamura, Yukie Tsuji, Manabu Iwabuchi, Takeshi Takahashi, Kensei Tobinai · 2017 · International Journal of Hematology
BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains
James L. Weaver, Leah M. Zadrozny, Kathleen L. Gabrielson, Kenrick M. Semple, Katherine I Shea, Kristina E. Howard · 2019 · Toxicological Sciences
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang · 2020 · Frontiers of Medicine
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Jennifer Nam Choi, Ronald Anderson, Ada Gabriela Blidner, Tim Cooksley, Michael Lawrence Dougan, Ilya G. Glezerman, Pamela Ginex, Monica Girotra, Dipti Gupta, Douglas Buckner Johnson et al. · 2020 · Supportive Care in Cancer
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Weilei Hu, Guosheng Wang, Yian Wang, Matthew John Riese, Ming You · 2020 · iScience
Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis
Náthali Felícia Mineiro dos Santos Garrett, Ana Cristina Carvalho da Costa, Elaine Barros Ferreira, Giovanni Battista Damiani, Paula Elaine Diniz dos Reis, Christiane Inocêncio Vasques · 2021 · PLoS ONE
Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
Yan Ma, Xiao Ma, Jingting Wang, Shanshan Wu, Jing Wang, Bangwei Cao · 2022 · World Journal of Surgical Oncology
Thyroid disorders in programmed death 1 inhibitor‐treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Emilia Sbardella, Marta Tenuta, Grazia Sirgiovanni, Daniele Gianfrilli, Carlotta Pozza, Mary Anna Venneri, Enrico Cortesi, Paolo Marchetti, Andrea Lenzi, Alain Jonathan Gelibter et al. · 2019 · Clinical Endocrinology
Impact of Concomitant Medication Use and Immune-Related Adverse Events on Response to Immune Checkpoint Inhibitors
Shipra Gandhi, Manu Raj Pandey, Nischala Ammannagari, Chong Wang, Mark J. Bucsek, Lamya Hamad, Elizabeth A. Repasky, Marc S. Ernstoff · 2020 · Immunotherapy
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer
Jake Sheraj Jacob, Barbara E. Dutra, Victor Garcia‐Rodriguez, Kavea Panneerselvam, Fiyinfoluwa O. Abraham, Fangwen Zou, Weijie Ma, Petros D. Grivas, John A. Thompson, Mehmet Altan et al. · 2021 · Journal of the National Comprehensive Cancer Network
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, Mathilde, Cugnet-Anceau, Christine, Dalle, Stephane, Chikh, Karim, Assaad, Souad, Disse, Emmanuel, Raverot, Gérald, Borson-Chazot, Françoise, Abeillon-du Payrat, Juliette · 2021 · Cancers
Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
Qi Cai, Gengwei Huo, Fuyi Zhu, Ping Yue, Dongqi Yuan, Peng Chen · 2022 · Human Vaccines & Immunotherapeutics
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Muhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai · 2018 · Journal for ImmunoTherapy of Cancer
Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
Emily Hinchcliff, David S. Hong, Hung Le, Gary B. Chisholm, Revathy B. Iyer, Aung Naing, Patrick Hwu, Amir Anthony Jazaeri · 2018 · Gynecologic Oncology
Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors
Ondřej Fiala, Ondřej Šorejs, Jan Šustr, Radek Kučera, Ondřej Topolčan, Jindřich Fínek · 2020 · Anticancer Research